

**Coalition for Epidemic Preparedness Innovations**  
**CEPI Interim Scientific Advisory Committee (SAC) London, UK conference**  
**June 1, 2018**  
**London, UK Conference**

**SUMMARY FROM SAC PROCEEDINGS (CEPI/SAC JUN 2018)**

The following Scientific Advisory Committee members participated:

<b>Committee members:</b>	<b>Non-voting members:</b>	
<ul style="list-style-type: none"> <li>• Helen Rees (Chair)</li> <li>• Jim Robinson (Vice Chair)</li> <li>• Alan Barrett</li> <li>• Daniel Brasseur</li> <li>• Christian Bréchet</li> <li>• Paula Bryant</li> <li>• Inger Damon</li> <li>• Mimi Darko</li> <li>• Michel DeWilde</li> <li>• John Edmunds</li> <li>• Penny Heaton</li> <li>• Thomas Kariuki</li> <li>• Phil Krause</li> <li>• Myron Levine</li> <li>• Connie Schmaljohn</li> <li>• Kenji Shibuya</li> <li>• Yves Levy</li> </ul>	<p><b><i>MNC representatives</i></b></p> <ul style="list-style-type: none"> <li>• Ali Allouche</li> <li>• Jean Lang</li> </ul> <p><b><i>Wellcome Trust</i></b></p> <ul style="list-style-type: none"> <li>• Josie Golding</li> </ul>	<p><b><i>Apologies</i></b></p> <ul style="list-style-type: none"> <li>• Ralf Clemens</li> <li>• Christian Happi</li> <li>• Johan von Hoof</li> <li>• Kathrin Jansen</li> <li>• Vasee Moorthy</li> <li>• Kathleen Neuzil</li> <li>• Peter Smith</li> </ul> <p><b><i>Unknown</i></b></p> <ul style="list-style-type: none"> <li>• George Fu Gao</li> </ul>
<p><b><i>Teleconference</i></b></p> <ul style="list-style-type: none"> <li>• Alash’le Abimiku</li> <li>• Stanley Plotkin</li> </ul>		

***CEPI Secretariat participants:*** Richard Hatchett (CEO), Eirik Bakka, Simone Blayer, Carolyn Clark, Theo Grace, Johan Holst, Nora Indrehus, Hinta Meijerink, Melanie Saville, Georges Thiry, Nadia Tornieporth. ***Teleconference:*** Trygve Danielsen, Dimitrios Gouglas, Karianne Johansen, Frederik Kristensen, Tung Thanh Le, Nicole Lurie, Henshaw Mandi, Sidra Shami, Solomon Abebe Yimer.

**Objectives** for the meeting:

1. To update the SAC on projections regarding CEPI’s current status, thinking, and plans
2. To update the SAC on CfP1 management and define next steps
3. To update the SAC on CfP2 review outcomes and define next steps
4. To discuss CEPI’s work on Lassa in the context of affected countries

**Update on CEPI’s portfolio**

The expected CEPI vaccine candidate portfolio was discussed in the context of CEPI’s financial projections (liquid assets and expected expenditures). By the end of the year, CEPI hopes to have over 30 vaccine candidates, with 20+ candidates targeting WHO Blueprint pathogens underway by the end of the year. At the time of the meeting, contracts had been signed with Themis, IAVI, Inovio, Profectus (Emergent); additional contracts were expected to be signed by the end of the year. The initial estimated cost for CFP1 was > MUSD 400 – but through negotiations this had been reduced by an estimated MUSD 90. The SAC noted the need for further discussion on how new and residual

funds beyond the current CEPI activities would be used, on responsibility for Phase 2b and Phase 3 trials. It was also noted that some SAC members will be asked to participate in Stage Gate Reviews.

### **Update on CfP1**

A presentation was given overviewing the CfP1 process, outcomes and the next steps. Key points raised in discussion:

- a) Does CEPI have capacity to man all these projects?
- b) Work in affected countries was encouraged to start as early as possible
- c) What the plans for mapping Lassa potential clinical sites was
- d) Small group capacities may be insufficient, and may depend upon significant CEPI support
- e) Early calls with regulators may be needed to train groups and ensure there is sufficient knowledge of Data Quality and what is needed
- f) The few laboratories which produce high quality may not have sufficient capacity – and that runs the risk of them being flooded with samples

The SAC agreed that:

- a) Some SAC members will be invited to participate in the Stage Gate review process and potentially on the reporting process
- b) CEPI will perform an analysis of needs and capacities (possibly through an external consulting group)
- c) Melanie Saville, Director of Vaccine Development, would circulate CEPI requirements for collaboration and precompetitive sharing
- d) It may be beneficial to discuss Phase III implementation
- e) A TC was proposed to address Lab capacities and needs and ensuring sufficient access and good quality. Yves Levy, Ali Allouche, Paula Bryant and Alan Barret were identified as interested SAC members representing regulators' views deemed necessary for engagement

### **Update on CfP2**

The SAC was presented with an overview of the CfP2 process, including outcomes of review and suggested next steps. After a roundtable discussion, the SAC decided that the review process was sufficiently robust.

Each of the 7 CfP2 applications invited in Step2 of the process was then discussed in considerable detail. The SAC recommended the following in terms of CEPI's portfolio:

- to move forward 6 proposals as presented
- to support one of these proposals under strict criteria and with a follow up process
- that CEPI consider addressing the potential portfolio gaps

### **Lassa Update and context**

The SAC was presented with the current state of the FIND collaboration with CEPI on Diagnostics. The SAC recommended that:

- a) Activities are needed to join the dots between Diagnostics, Standards and CfP1
- b) Longitudinal sample collection should be encouraged
- c) Christian Brechot nominated to support and guide this process
- d) Tom Karauki, Alan Barrett and Connie Schmaljohn volunteered to work on the Diagnostics/ Biobanking discussion, and regulators need to be identified to engage into the process

The next SAC was planned be held by teleconference on 23 August 2018